Spotlight On... Silicon Valley Bank: Drug delivery devices increasingly attracting venture capital; and more...

Drug delivery devices earned 6 VC deals in 2015, worth $60 million, putting them on Silicon Valley Bank's list of the top 10 device investments by indication. SVB expects the category to continue gaining traction. "Drug delivery is on the list for the first time," Healthcare Practice Managing Director Jonathan Norris told FierceMedicalDevices. "I think that trend will continue--finding ways of delivering noninvasive or minimally therapies. We're seeing a lot of investment in minimally invasive devices to take market share from drugs or unique tech for drug delivery." More from FierceMedicalDevices | The report (PDF)

> The FDA is meeting today, Jan. 12, to review Braeburn's subdermal implant for the delivery of buprenorphine/naloxone as a maintenance treatment for opioid addiction, dubbed Probuphine. The submission was made on behalf of development partner Titan Pharmaceuticals. In 2013, made a surprising rejection of the implant, expressing concerns about the trial design and "human factors testing of the training associated with Probuphine's insertion and removal." More | Meeting docs

> The U.K.'s Glide Technologies announced that it has completed a preclinical proof-of-concept study of its novel solid dose formulation of exenatide, in the fight against Type 2 diabetes. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.